Retrospective Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Jan 26, 2023; 11(3): 556-565
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.556
Table 1 Comparison of scores between and within groups (mean ± SD)
Indicators
Time
Control group (n = 34)
Observation group (n = 34)
t value
P value
APACHE II score (points)Before treatment17.58 ± 3.2117.62 ± 3.080.0520.958
After treatment13.25 ± 2.14a10.11 ± 1.83a6.5020.000
MODS score (points)Before treatment14.55 ± 2.5314.48 ± 2.610.1120.911
After treatment9.89 ± 1.67a8.21 ± 1.43a4.4560.000
NIHSS score (points)Before treatment19.97 ± 2.0720.01 ± 2.130.0790.938
After treatment10.74 ± 1.74a8.56 ± 1.55a5.4550.000
TCM syndrome points (points)Before treatment24.12 ± 2.5823.97 ± 2.610.2380.812
After treatment11.41 ± 1.25a7.85 ± 1.06a12.6660.000
Table 2 Comparison of complement and immunoglobulins system indexes between and within groups (mean ± SD)
Indicators
Time
Control group (n = 34)
Observation group (n = 34)
t value
P value
Complement C3 (g/L)Before treatment1.04 ± 0.121.02 ± 0.130.6590.512
After treatment1.28 ± 0.17a1.43 ± 0.21a3.2370.002
Complement C4 (g/L)Before treatment0.22 ± 0.050.23 ± 0.040.9110.366
After treatment0.31 ± 0.07a0.37 ± 0.09a3.0680.003
IgM (g/L)Before treatment0.74 ± 0.110.73 ± 0.140.3270.744
After treatment1.11 ± 0.15a1.36 ± 0.18a6.2210.000
IgG (g/L)Before treatment9.74 ± 0.419.68 ± 0.380.6260.534
After treatment10.64 ± 0.52a11.47 ± 0.61a6.0380.000
Table 3 Comparison of intestinal mucosal barrier function indexes between groups and within groups (mean ± SD)
Indicators
Time
Control group (n = 34)
Observation group (n = 34)
t value
P value
DAO (U/mL)Before treatment3.28 ± 0.343.31 ± 0.300.3860.701
After treatment4.15 ± 0.38a4.63 ± 0.45a4.7520.000
D-LA (mmol/L)Before treatment0.18 ± 0.070.19 ± 0.060.6320.529
After treatment0.27 ± 0.08a0.36 ± 0.10a4.0980.000
Lipopolysaccharide (ng/L)Before treatment17.41 ± 4.5217.35 ± 4.670.0540.957
After treatment11.14 ± 2.05a8.21 ± 1.61a6.5540.000
Table 4 Comparison of calcitonin gene-related peptide, ubiquitin carboxyl-terminal hydrolase 1, tumor necrosis factor-α, interleukin-2, interleukin-8 between and within groups (mean ± SD)
Indicators
Time
Control group (n = 34)
Observation group (n = 34)
t value
P value
CGRP (pg/mL)Before treatment21.52 ± 5.3620.97 ± 5.710.4090.683
After treatment28.26 ± 6.17a36.58 ± 6.78a5.2920.000
UCH-L1 (µg/L)Before treatment0.40 ± 0.180.41 ± 0.130.2630.794
After treatment0.25 ± 0.11a0.17 ± 0.10a3.1380.003
TNF-α (pg/mL)Before treatment44.52 ± 5.8942.97 ± 6.011.0740.287
After treatment21.02 ± 4.15a14.63 ± 3.85a6.5820.000
IL-2 (pg/mL)Before treatment15.89 ± 2.1615.81 ± 2.240.1500.881
After treatment10.13 ± 1.92a6.78 ± 1.52a7.9770.000
IL-8 (pg/mL)Before treatment5.23 ± 0.825.18 ± 0.910.2380.813
After treatment4.64 ± 0.53a3.47 ± 0.42a10.0880.000
Table 5 Comparison of intestinal flora between groups and within groups (mean ± SD)
Indicators
Time
Control group (n = 34)
Observation group (n = 34)
t value
P value
Bifidobacterium (× 107 CFU)Before treatment9.74 ± 1.149.67 ± 1.210.2460.807
After treatment11.11 ± 1.25a12.78 ± 1.34a5.3140.000
Lactobacillus (× 107 CFU)Before treatment9.42 ± 1.149.36 ± 1.080.2230.824
After treatment10.78 ± 1.27a12.63 ± 1.41a5.6850.000
Enterococcus (× 107 CFU)Before treatment8.85 ± 1.148.79 ± 1.210.2100.834
After treatment9.75 ± 1.21a11.41 ± 1.37a5.2960.000
Bacteroides (× 107 CFU)Before treatment7.96 ± 0.218.02 ± 0.261.0470.299
After treatment6.41 ± 0.17a6.02 ± 0.14a10.3260.000
Table 6 Comparison of the incidence of gastrointestinal complications and pressure ulcers between groups, n (%)
Group
Gastrointestinal complications
Pressure ulcer
Total complications
Diarrhea
Constipate
Gastrointestinal bleeding
Vomit
Control group (n = 34)2 (5.88)1 (2.94)1 (2.94)3 (8.82)1 (2.94)8 (23.53)
Observation group (n = 34)1 (2.94)0 (0.00)0 (0.00)2 (5.88)0 (0.00)3 (8.82)
χ2 value2.711
P value0.100
Table 7 Comparison of ventilator-associated pneumonia incidence, weaning success rate, hospital stay, and 28-d mortality between groups, n (%)
Group
Incidence of VAP
Offline success rate
Hospital stay (d)
28 d case fatality rate (%)
Control group (n = 34)11 (32.35)18 (52.94)20.56 ± 5.827 (20.59)
Observation group (n = 34)5 (14.71)23 (67.65)16.78 ± 4.532 (5.88)
χ2/t value2.9421.5362.9893.202
P value0.0860.2150.0040.074